Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 9—September 2021
Synopsis

Epidemiology, Clinical Features, and Outcomes of Coccidioidomycosis, Utah, 2006–2015

Adrienne CareyComments to Author , Morgan E. Gorris, Tom Chiller, Brendan Jackson, Wei Beadles, and Brandon J. Webb
Author affiliations: University of Utah School of Medicine, Salt Lake City, Utah, USA (A. Carey); Los Alamos National Laboratory, Los Alamos, New Mexico, USA (M. Gorris); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (T. Chiller, B. Jackson); Utah Department of Health, Salt Lake City (W. Beadles); Intermountain Healthcare, Salt Lake City (B. Webb); Stanford University School of Medicine, Palo Alto, California, USA (B. Webb)

Main Article

Figure 2

Annual statewide coccidioidomycosis incidence calculated from cases reported to the Utah Department of Health, Utah, 2009–2015. The dotted line represents the line of best fit for the data with an R2 of 0.018.

Figure 2. Annual statewide coccidioidomycosis incidence calculated from cases reported to the Utah Department of Health, Utah, 2009–2015. The dotted line represents the line of best fit for the data with an R2 of 0.018.

Main Article

Page created: June 09, 2021
Page updated: August 17, 2021
Page reviewed: August 17, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external